company background image
CLNN

Clene NasdaqCM:CLNN Stock Report

Last Price

US$3.63

Market Cap

US$230.5m

7D

6.8%

1Y

-50.1%

Updated

16 Aug, 2022

Data

Company Financials +
CLNN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance2/6
Financial Health0/6
Dividends0/6

CLNN Stock Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

Clene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clene
Historical stock prices
Current Share PriceUS$3.63
52 Week HighUS$8.60
52 Week LowUS$1.93
Beta0.42
1 Month Change-19.33%
3 Month Change63.51%
1 Year Change-50.14%
3 Year Change-64.72%
5 Year Changen/a
Change since IPO-62.38%

Recent News & Updates

Jul 19

Clene ALS therapy gets EMA panel backing for orphan drug status

A panel of the European Medicines Agency (EMA) recommended granting orphan drug designation to Clene (NASDAQ:CLNN) CNM-Au8 to treat amyotrophic lateral sclerosis (ALS). The EMA's Committee for Orphan Medicinal Products (COMP) decision was was backed by data from a phase 2 trial called RESCUE-ALS and preclinical ALS models, the company said in a July 19 press release. ALS is a progressive nervous system disease affecting the nerve cells in the brain and spinal cord, causing loss of muscle control. In EU the orphan drug status is given to therapies aimed at treating a serious or life-threatening disease affecting not more than five in 10K people in the EU. The designation has benefits, including 10 years of market exclusivity, if approved. CLNN -4.97% to $4.59 premarket July 19

Shareholder Returns

CLNNUS BiotechsUS Market
7D6.8%1.4%3.6%
1Y-50.1%-19.6%-9.6%

Return vs Industry: CLNN underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: CLNN underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is CLNN's price volatile compared to industry and market?
CLNN volatility
CLNN Average Weekly Movement20.9%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CLNN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: CLNN's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a99Rob Etheringtonhttps://clene.com

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company’s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications.

Clene Fundamentals Summary

How do Clene's earnings and revenue compare to its market cap?
CLNN fundamental statistics
Market CapUS$230.51m
Earnings (TTM)US$15.48m
Revenue (TTM)US$374.00k

14.9x

P/E Ratio

617.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLNN income statement (TTM)
RevenueUS$374.00k
Cost of Revenue-US$509.00k
Gross ProfitUS$883.00k
Other Expenses-US$14.60m
EarningsUS$15.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin236.10%
Net Profit Margin4,138.77%
Debt/Equity Ratio-3,598.6%

How did CLNN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CLNN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLNN?

Other financial metrics that can be useful for relative valuation.

CLNN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue617.5x
Enterprise Value/EBITDA-4.6x
PEG Ratio0.2x

Price to Earnings Ratio vs Peers

How does CLNN's PE Ratio compare to its peers?

CLNN PE Ratio vs Peers
The above table shows the PE ratio for CLNN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average18x
XOMA XOMA
21.6x60.5%US$206.1m
LJPC La Jolla Pharmaceutical
39x59.0%US$154.6m
MREO Mereo BioPharma Group
8.5x-30.2%US$130.4m
SESN Sesen Bio
3x8.6%US$143.1m
CLNN Clene
14.9x85.0%US$230.5m

Price-To-Earnings vs Peers: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the peer average (18x).


Price to Earnings Ratio vs Industry

How does CLNN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the US Biotechs industry average (16x)


Price to Earnings Ratio vs Fair Ratio

What is CLNN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLNN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.9x
Fair PE Ratio66.2x

Price-To-Earnings vs Fair Ratio: CLNN is good value based on its Price-To-Earnings Ratio (14.9x) compared to the estimated Fair Price-To-Earnings Ratio (66.2x).


Share Price vs Fair Value

What is the Fair Price of CLNN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLNN ($3.63) is trading below our estimate of fair value ($131.38)

Significantly Below Fair Value: CLNN is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Clene forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


85.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLNN's forecast earnings growth (85% per year) is above the savings rate (1.9%).

Earnings vs Market: CLNN's earnings (85% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: CLNN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CLNN's revenue (83.3% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: CLNN's revenue (83.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLNN is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Clene performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


24.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CLNN has a large one-off gain of $66.0M impacting its June 30 2022 financial results.

Growing Profit Margin: CLNN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CLNN has become profitable over the past 5 years, growing earnings by 24.8% per year.

Accelerating Growth: CLNN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CLNN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: CLNN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Clene's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CLNN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CLNN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CLNN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CLNN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: CLNN's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if CLNN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Clene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLNN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLNN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CLNN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Rob Etherington (55 yo)

9.33yrs

Tenure

US$5,101,808

Compensation

Mr. Robert Etherington, also known as Rob, MBA, serves as President, Chief Executive Officer and Director at Clene Inc. since April 2013. He serves as the Chief Executive Officer and President of Clene Nan...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD5.10M) is above average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLNN's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: CLNN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CLNN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.


Top Shareholders

Company Information

Clene Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Clene Inc.
  • Ticker: CLNN
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$230.512m
  • Shares outstanding: 63.50m
  • Website: https://clene.com

Number of Employees


Location

  • Clene Inc.
  • 6550 South Millrock Drive
  • Suite G50
  • Salt Lake City
  • Utah
  • 84121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.